echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Cinda Bio's dual-specific fusion protein was approved for clinical use

    Cinda Bio's dual-specific fusion protein was approved for clinical use

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China shows that Cinda Biologics Class 1 new drug IBI302 has obtained the implied approval of a clinical trial and plans to develop the treatment of diabetic macular edema (DME)
    .


    According to Cinda Bio's official information, IBI302 is a "first-in-class" drug under development independently developed by the company, and is the world's first bispecific fusion protein targeting vascular endothelial growth factor (VEGF) and complement


    The clinical research indication approved by IBI302 this time is: diabetic macular edema
    .


    Public information shows that diabetic macular edema is one of the main causes of vision loss in adults


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.